Home

Connecta Therapeutics drug for fragile X syndrome receives orphan designation from European Medicines Agency

Barcelona, 06 September 2021 CTH120, designed using artificial intelligence techniques, will start Phase I in 2022 CTH120 designation as orphan drug validates and empowers Connecta Therapeutics's strategy in neurodevelopmental diseases   CTH120 Connecta Therapeutics has received approval as orphan drug from the European Medicines Agency (EMA) to treat fragile...

Continue reading

Connecta Therapeutics, the CRG and the IMIM join forces to develop an innovative treatment for fragile X syndrome

Barcelona The public-private consortium has obtained a grant of €1.97 million from the Spanish National Innovation Agency Preclinical studies have shown that the CTH120 molecule can modulate neuroplasticity, the ability of cells of the nervous system to regenerate in response to pathological influences   The public-private consortium formed by...

Continue reading

Connecta Therapeutics, the CRG and the IMIM receive €1.97 million from the Spanish National Innovation Agency to develop a treatment for fragile X syndrome

Barcelona The public-private consortium has earned this grant through the 2019 “Collaboration Challenges” programme   The public-private consortium formed by the biotech company Connecta Therapeutics, the Centre for Genomic Regulation (CRG) and the Hospital del Mar Medical Research Institute (IMIM) has received a grant for 1,970,520 Euro from...

Continue reading